HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of IL-4/IL-13 does not enhance the efficacy of allergen immunotherapy in murine allergic airway inflammation.

AbstractBACKGROUND:
Successful allergen-specific immunotherapy (SIT) is associated with reduced Th2 cytokine production and the induction of IL-10-producing regulatory T cells. To improve treatment efficacy, we investigated the impact of an IL-4/IL-13 inhibitor during SIT.
METHODS:
BALB/c mice were sensitized intranasally with ovalbumin (OVA) for 4 weeks. Subsequently, they were subjected to intranasal SIT, with OVA being administered at doses increasing from 1 mug to 1 mg over 3 weeks with or without an IL-4/IL-13 inhibitor. Serum OVA-specific antibodies were measured and bronchoalveolar lavage (BAL) fluids were checked for airway eosinophilia. Subsequently, lung tissue was examined histologically for inflammatory infiltrates. Cytokines were detected in BAL fluids and spleen cell cultures. Furthermore, CD4 CD25 double-positive spleen T cells were checked for intracellular IL-10 production by flow cytometry.
RESULTS:
OVA sensitization resulted in persistent IgE synthesis and an eosinophil-rich allergic airway inflammation combined with increased IL-4 and IL-5 levels. Therefore, intranasal SIT could efficiently reverse the allergic phenotype. This was associated with decreased IL-4 and IL-5 levels, and increased IL-10 levels in BAL fluids as well as increased amounts of IL-10-producing CD25+ regulatory T cells. However, mice treated with the IL-4/IL-13 inhibitor during SIT did not produce significantly different results .
CONCLUSION:
The use of an IL-4/IL-13 inhibitor as an adjuvant for SIT did not enhance anti-allergic effects. Thus, the observed reversal of Th2 responses during SIT may not be the keystone for successful therapy, but rather other factors, e.g. IL-10-producing regulatory T cells, may be crucial.
AuthorsTea Gogishvili, Christian Hahn, Julia Meinhard, Andreas Hohaus, Klaus Erb, Walter Sebald, Eva B Bröcker, Susanne M Grunewald
JournalInternational archives of allergy and immunology (Int Arch Allergy Immunol) Vol. 142 Issue 2 Pg. 165-74 ( 2007) ISSN: 1018-2438 [Print] Switzerland
PMID17077644 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2007 S. Karger AG, Basel.
Chemical References
  • Interleukin-13
  • Interleukin-2 Receptor alpha Subunit
  • Interleukin-10
  • Interleukin-4
  • Ovalbumin
Topics
  • Administration, Intranasal
  • Animals
  • Asthma (immunology, pathology, prevention & control)
  • Bronchoalveolar Lavage Fluid (chemistry, immunology)
  • Desensitization, Immunologic
  • Enzyme-Linked Immunosorbent Assay
  • Eosinophils (immunology)
  • Flow Cytometry
  • Hypersensitivity (prevention & control)
  • Inflammation (prevention & control)
  • Interleukin-10 (biosynthesis, immunology)
  • Interleukin-13 (antagonists & inhibitors)
  • Interleukin-2 Receptor alpha Subunit (immunology, metabolism)
  • Interleukin-4 (antagonists & inhibitors)
  • Lung (cytology, immunology, pathology)
  • Mice
  • Mice, Inbred BALB C
  • Ovalbumin (administration & dosage, immunology)
  • T-Lymphocytes, Regulatory (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: